Targeting patients undergoing angioplasty for thrombus inhibition: A cost-effectiveness and decision support model

Circulation

Volumn 102, Issue 4, 2000, Pages 392-398

  Weintraub, William S ^a,c   Thompson, Trevor D ^d   Culler, Steven ^a   Boccuzzi, Stephen J ^b   Becker, Edmund R ^a   Kosinski, Andrzej S ^a   Mahoney, Elizabeth ^d  

^a EMORY UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Angioplasty; Cost benefit analysis; Platelet aggregation inhibitors

Indexed keywords

ANTITHROMBOCYTIC AGENT; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL FEE; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL;

EID: 0034713882     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.4.392     Document Type: Article

References (18)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Tcheng JE, Harrington RA, Kottke-Marchant K, et al, for the IMPACT investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention: IMPACT Investigators. Circulation. 1995; 91:2151-2157.
3. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
4. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
5. The Epilog Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
6. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
7. Campeau L. Grading of angina pectoris. Circulation. 1975;54:522-523. Letter.
8. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 8th ed. Boston: Little, Brown and Co; 1979.
9. Weintraub WS, Kosinski AS, Brown CL III, et al. Can restenosis be predicted after coronary angioplasty from clinical variables? J Am Coll Cardiol. 1993;21:6-14.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Becker ER, Mauldin PD, Bernadino ME. Using physician work RVUs to profile surgical packages: methods and results for kidney transplant surgery. Best Pract Benchmarking Healthc 1996;1:1-7.
12. Commerce Clearing House. Physician's Medicare Fee Schedule, January 1, 1995. Chicago, Ill: CCH Incorporated; 1994:5.
13. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
14. Weinstein WC, Fineberg. Clinical Decision Analysis. Philadelphia, Pa: Saunders; 1980:256-261.
15. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
16. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: evaluation of platelet IIb/IIIa inhibitors for stenting. Lancet. 1998;352:87-92.
17. Weintraub WS, Warner CD, Mauldin PD, et al. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. Am J Manag Care. 1997;3:743-749.
18. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.